- Climate Change
- Reducing Crop Protection’s Environmental Impact
- Empowering Smallholder Farmers
- Food System Resilience
- Education & Outreach
- Sustainable Agriculture in practice: Bayer Forward Farms
- Genetically Modified Crops and Bayer
- News & Stories
February 24, 2021
Bayer to Divest Environmental Science Professional Business and Further Strengthen Leadership Team of Crop Science Division
Monheim, February 24, 2021 – Bayer today announced a series of decisions to accelerate the strategy implementation of its Crop Science division. In order to focus on its core agricultural business, this includes the intent to divest the company’s Environmental Science Professional business. It is a global leader offering environmental solutions to control pests, disease and weeds in non-agricultural areas such as vector control, professional pest management, industrial vegetation management, forestry, and turf and ornamentals. The Environmental Science Professional business had sales of approx. 600 million Euros in 2019.
To further drive performance and growth in the division’s most important commercial region, Bayer has named Dr. Jacqueline M. Applegate to lead the Crop Science North America region effective March 1, 2021. She currently heads the division’s Environmental Science and Vegetable Seeds businesses and has a strong track record of commercial execution and of driving transformation. In addition to her appointment, the company named Dr. Jeremy Williams, currently Global Head of Plant Biotechnology at Crop Science, as new head of the Climate Corporation and Digital Farming, and Tom Armitage from Mondelez as head of Global Communications for Crop Science. Both are effective March 15, 2021. All three leaders will join the Crop Science Executive Leadership Team and will play key roles in accelerating the division’s transformation.
In addition, Bayer appointed Gilles Galliou, currently head of commercial operations for Bayer Vegetable Seeds Americas, to lead the Environmental Science business and the planned divestment. The global Environmental Science business will be headquartered in Cary, North Carolina, effective June 1, 2021. Inci Dannenberg, currently head of global strategic marketing for Vegetable Seeds, was also appointed to run the Crop Science global Vegetable Seeds business, which is headquartered in St. Louis, Missouri. Both appointments are effective from March 1, 2021.
“With the announced portfolio and leadership changes, and important new product approvals for soybeans, corn and cotton in the Americas, we are now shifting gears from integration to growth acceleration. We are laser-focused on commercial execution and on transforming agriculture through innovation that benefits farmers, consumers and our planet,” said Liam Condon, Member of the Board of Management of Bayer AG and President of the Crop Science division. “Like farmers everywhere, we have faced challenges in the past few years; however, I am very excited about the outlook for our Crop Science business. The global coronavirus pandemic has made it clear how important agriculture and a sustainable food system are, and the crucial role science can play in solving difficult problems. Driving innovation, accelerating the digital transformation of agriculture and helping decarbonize the food system are at the core of our vision to feed a growing population without starving the planet.”
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.